|
|
| Mesenchymal stem cells (MSCs) are a tremendously exciting area of regenerative medicine due to their ability to differentiate, reduce inflammation and fibrosis, promote tissue repair, modulate the immune response, and produce therapeutic exosomes. Beyond their use as cellular therapeutics, MSCs are finding use within emerging applications, such as tissue engineering, organoid production, exosome production, cosmeceutical development, and cultured meat production.
Today, 12 MSC-based cell therapies are available to be marketed globally. This includes 11 full approvals and a 12th conditional approval within China. Only one of these products is approved for use within the U.S., Mesoblast's Ryoncil (remestemcel-L-rknd), which received FDA approval in December 2024. A 13th product, Takeda’s Alofisel, was approved by the European EMA in 2018, but it was voluntarily withdrawn on December 13, 2024.
To date, globally approved MSC-based cell therapies include:
Republic of Korea:
- Queencell from Anterogen
- Cellgram AMI from Pharmicell
- Cupistem from Anterogen
- Cartistem from Medipost
- NeuroNataR from Corestem
Japan:
- Temcell HS from JCR Pharmaceuticals
- Stemirac from Nipro Corporation
Europe:
- Holoclar from Chiesi Farmaceutici
- *Previously, Alofisel from Takeda/TiGenix was approved by the EMA, but it was withdrawn in December 2024.
India:
- Stempeucel from Stempeutics
Iran:
- MesestroCell from Cell Tech Pharmed
Canada and the U.S. have approved:
- Prochymal, also branded as Ryoncil (remestemcel-L) from Mesoblast
China has given Conditional Approval to one product:
- Ruibosheng, an umbilical cord-derived MSC product (amimestrocel injection) from Platinum Life Excellence
Market competitors have also developed 17 biomaterial-based MSC and MSC progenitor products, which are predominantly being used for orthopedic indications.
MSCs have also encroached into other industries and markets. Cosmeceutical companies such as L’Oréal and Johnson & Johnson are now investing heavily into the production of makeup and personal care products that leverage MSCs for their growth factors and cytokines. To date, the cosmetic industry has released 20 products making use of MSCs from conditioned or spent culture media.
Furthermore, the clean meat industry is using muscle precursor cells (satellite cells) derived from MSCs to produce cultured meat products. The industry is also using MSC-produced fat (adipocytes) to enhance the taste of cultured meat products.
In other news, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, supporting large-scale therapeutic development. Today, there are at least eight companies involved with the development of iPSC-derived MSC therapeutics (iMSCs), including Cynata Therapeutics and Fujifilm CDI, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Citius Pharmaceuticals, Eterna Therapeutics, Implant Therapeutics, and Kiji Therapeutics.
Of course, the market for MSC-based research products is also booming, with competitors like RoosterBio, PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC leading the charge.
Finally, there are at least 125 market competitors who are are developing various types of MSC-based products, services, therapeutics, and technologies. Within this rapidly changing landscape, having a thorough understanding of the competition, their proprietary technology platforms, and their strengths and weaknesses is essential.
This global strategic report reveals detailed market size figures for the global MSC market, segmented by geography and business segment, and accompanied by future forecasts through 2031.
For 48 hours only, you can claim this report for an unusual 20% off. Remember to act fast, because this offer expires soon!
Be Great, The BioInformant Team
p.s. Interested in other market areas, such as iPSCs, CAR-T, exosomes, cord blood and tissue, regenerative medicine, and beyond?
|
|
|
